The clinical and economic rationale for the efficiency of using bioplastics in the treatment of patients with neuropathic diabetic foot syndrome

DOI: https://doi.org/10.29296/25877305-2021-12-12
Download full text PDF
Issue: 
12
Year: 
2021

G. Alyapyshev Ulyanovsk Regional Clinical Hospital

Objective. To study the short-term and long-term results of treatment in patients with Wagner grade 3 neuropathic diabetic foot syndrome (DFS) in a day hospital and, by carrying out a clinical and economic analysis, to evaluate the efficiency of using the bioplastic G-derm in the topical treatment of chronic wounds in these patients. Subjects and methods. The investigation enrolled 64 patients with Wagner grade 3 neuropathic DFS who were divided into 2 groups: a study group (n = 33) that was topically treated with the bioplastic G-derm and a comparison group (n = 31) that received the standard treatment with hydrocolloid dressings. The investigation results were used to comparatively calculate the average cost of complex surgical treatment in both groups. Results. In a day hospital, the short-term results of treatment with the bioplastic G-derm demonstrated a rapider wound epithelialization in the study group than in the comparison group treated with hydrocolloid dressings. The long-term results of using the bioplastic material G-derm also showed high efficiency. Conclusion. The conducted clinical and economic analysis has shown that the treatment with bioplastic G-derm in DFS patients, despite its relatively high cost as compared with that with hydrocolloid dressings, is effective from both clinical and economic points of view due to the rapid regeneration of wound processes.
Keywords: 
therapy
diabetes mellitus
diabetic foot syndrome
the bioplastic G-derm
hydrocolloid dressing
chronic foot wound

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Guariguata L., Whiting D.R., Hambleton I. et al. Global estimates if diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103 (2): 137–49. DOI: 10.1016/j.diabres.2013.11.002
  2. Krivoschekov E.P., El'shin E.B. Primenenie sovremennyh perevjazochnyh sredstv v lechenii ran diabeticheskoj stopy. Tol'jattinskij meditsinskij konsilium. 2017; 3 (4): 38–40 [Krivoshchekov E.P, Elshin E.B. The use of modern dressing materials in treatment of diabetic foot ulcers. Tolyatti medical consilium. 2017; 3 (4): 38–40 (in Russ.)].
  3. Galstjan G.R., Mitish V.A., Sitkin I.I., i dr. Vedenie bol'nyh s saharnym diabetom i nejroishemicheskoj formoj sindroma diabeticheskoj stopy v real'noj klinicheskoj praktike (klinicheskij sluchaj). Diagnosticheskaja i interventsionnaja radiologija. 2010; 4 (1): 87–92 [Galstyan G.R., Mitish V.A., Sitkin I.I. et al. Clinical management of patients with diabetis and neuroishemic form of diabetic foot syndrome in clinical practice. Diagnostic and interventional radiology. 2010; 4 (1): 87–92 (in Russ.)].
  4. Mitish V.A., Pashalova Ju.S., Garjaeva V.V., i dr. Opyt uspeshnogo kompleksnogo lechenija patsienta s diabeticheskoj nejroosteoartropatiej srednego otdela stopy v stadii gnojnyh oslozhnenij. Rany i ranevye infektsii. Zhurnal im. prof. B.M.Kostjuchenka. 2017; 4 (4): 28–37 [Mitish V.A., Paskhalova Yu.S., Garyaeva V.V., et al. The successful complex treatment diabetic neuroosteoarthropathy of the middle part of the foot in the stage of purulent complications. Wounds and wound infections. The prof. B.M. Kostyuchenok journal. 2017; 4 (4): 28–37 (in Russ.)]. DOI: 10.25199/2408-9613-2017-4-4-28-37
  5. Antsiferov M.B., Kosheljagina E.Ju. Sindrom diabeticheskoj stopy: diagnostika, lechenie i profilaktika. M.: Meditsinskoe informatsionnoe agentstvo, 2013; 304 s. [Antsiferov M., Koshelyagina E. Diabetic foot syndrome: diagnostics, treatment and prevention. M.: Medetsinskoe informatsionnoe agenstvo, 2013; 304 p. (in Russ.)].
  6. Krivoshchekov E., Elshin E., Ganja N. et al. The positive experience of the local treatment of wounds neuropathic form of diabetic foot syndrome. Dan Sci J. 2018; 1 (13): 27–30.
  7. Krivoschekov E. P., El'shin E. B., Romanov V. E. Patogeneticheskoe lechenie oslozhnenij sindroma diabeticheskoj stopy. Prakticheskaja meditsina. 2017; 4 (105): 77–84 [Krivoshchekov E.P., Elshin E.B., Romanov V.E. Pathogenetic treatment of complications of diabetic foot syndrome. Practice medicine. 2017; 4 (105): 77–84 (in Russ.)].
  8. Cavanagh P., Attinger C., Abbas Z. et al. Cost of treating diabetic foot ulcers in five different countries. Diab Metab Res Rev. 2012; 28 (1): 107–11. DOI: 10.1002/dmrr.2245
  9. Galstjan G.R., Sergeeva S.V., Ignat'eva V.I., i dr. Kliniko-ekonomicheskoe obosnovanie stoimosti kvoty na lechenie patsientov s sindromom diabeticheskoj stopy. Saharnyj diabet. 2013; 16 (3): 71–83 [Galstyan G.R., Sergeeva S.V., Ignat’eva V.I. et al. Clinical and economical grounds of budgetary quotation for patients with diabetic foot syndrome. Diabetes mellitus. 2013; 16 (3): 71–83 (in Russ.)]. DOI: 10.14341/2072-0351-820
  10. Zelenova O.V., Mitish V.A., Pashalova Ju.S, i dr. Patsientskaja model' dlja hirurgicheskogo lechenija i reabilitatsii sindroma diabeticheskoj stopy. Rany i ranevye infektsii. Zhurnal im. prof. B.M. Kostjuchenka. 2018; 5 (2): 58–79 [Zelenova O.V., Mitish V.A., Paskhalova Yu.S. et al. Patient’s model for the surgical treatment and rehabilitation of diabetic foot syndrome. Wounds and wound infections. The prof. B.M. Kostyuchenok journal. 2018; 5 (2): 58–79 (in Russ.)]. DOI: 10.25199/2408-9613-2018-5-2-58-79
  11. Burgos-Alonso N., Lobato I., Hernández I. et al. Adjuvant Biological Therapies in Chronic Leg Ulcers. Int J Mol Sci. 2017; 18 (12): 2561. DOI: 10.3390/ijms18122561